Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection...
1 week ago

Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday.
6 days ago

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.
4 days ago

H.C. Wainwright analyst Ananda Ghosh maintains a Buy rating on ProQR with a price target of $12.00 due to the company's strategic...
6 days ago

LEIDEN, Netherlands (AP) — LEIDEN, Netherlands (AP) — ProQR Therapeutics NV (PRQR) on Thursday reported a loss of $13.8 million in its...
1 week ago

ProQR Therapeutics N.V. (NASDAQ:PRQR), a biotechnology company specializing in RNA editing, is poised at a critical juncture as it advances...
3 days ago

ProQR Therapeutics NV PRQR reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, lower than the same...
1 week ago

ProQR submits first RNA editing clinical trial application, maintains €120M cash runway into 2027. Q4 data readout ahead.
1 week ago

NasdaqCM:PRQR 1 Year Share Price vs Fair Value Explore ProQR Therapeutics's Fair Values from the Community and select...
1 week ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated...
3 weeks ago